Cancer in the cervix, which is the lower part of the uterus, is called cervical cancer. Its two primary types are squamous cells cancer and adenocarcinoma. 80% to 90%, i.e., a majority of cervical cancer cases fall under the former category. The latter is less common, constituting 10% to 20% of cases; however, the incidence of adenocarcinoma is rising predominantly in younger girls. Cervical cancer is a common type of cancer occurring in women across the world. A major cause is infection by human papillomavirus (HPV) which is found in 99% of cervical cancer cases.
View Report –
Cervical cancer can be prevented via widespread immunization with the HPV vaccine, which prevents infection from high-risk HPV strains and also offers protection against the low-risk ones which cause genital warts. The Centers for Disease Control and Prevention (CDC) has recommended that the HPV vaccine be administered to girls and boys falling in the age group of 11 years to 12 years. Vaccination at an early stage of life, during teenage, is highly effective. In October 2016, the CDC updated the schedule of the HPV vaccination. It recommends that all teens and adolescents falling between the ages of 9 and 14 should receive two doses of HPV vaccination within a gap of six months.
Request Brochure of Cervical Cancer Therapeutics Market Report
- Global Cervical Cancer Therapeutics Market: Drivers and Restraints
The cancer prophylactic market has witnessed significant growth in developed countries in last decade. Awareness initiatives taken by governments to educate women about early diagnostic test and treatment also increased. This helped in prevention of cervical cancer progression into aggressive or advanced stages. This restrained the cancer treatment market. Rise in prevalence, awareness, and advancement in treatment and various treatments available drive the cervical cancer therapeutics market.
- Global Cervical Cancer Therapeutics Market: Key Players
Key players operating in the global cervical cancer therapeutics market are Novartis AG, Genentech USA, AstraZeneca plc, Eli Lilly and Company, Pfizer, Inc., Allergan, Bristol-Myers Squibb Company, Actavis Pharma Company, and GlaxoSmithKline plc.